New strategy for defeating neuroblastoma found

New strategy for defeating neuroblastoma
The images shows Lipid droplet accumulation (red) in neuroblastoma cells following treatment with a MYC-targeting molecule. Credit: Anna Frenzel, Karolinska Institutet

Researchers at Karolinska Institutet in Sweden have found a promising strategy for defeating neuroblastoma – a malignant form of cancer in children – that focuses on the so-called MYCN protein. A specific chemical molecule helps to break down MYCN, which either kills the cancer cell or makes it mature into a harmless neuron. The discovery, which is published in the scientific journal PNAS, raises hopes for new and more effective treatments in the future.

Neuroblastoma is the third most common form of cancer in children. It usually develops before the age of two and affects around two dozen children per year in Sweden and around 800 in the US. The tumours are normally located in the , but in very young infants they can sometimes spread over the entire body. Current therapies are tough and have serious side effects, and for many of the patients the prognosis is poor. In its most aggressive form only a minority survive, which makes finding particularly urgent.

In the case of neuroblastoma, extra copies of the gene that encodes the MYCN protein are normally found in the cancer cell. This in turn is a clear indication of a , as it has long been known that the incorrect activation of the MYCN and similar MYC genes causes cancer. The strategy of the research group for defeating the disease was therefore to identify substances that prevent MYC-triggered cell division or that kill in an MYC-specific manner.

"We have found that a small chemical molecule, that is known from previous studies to inhibit the activity of the c-MYC-protein, also inhibits the activity of MYCN," says Principal Investigator Marie Arsenian Henriksson, Professor of molecular tumour biology at Karolinska Institutet. "The substance disrupts the binding between MYCN and another protein called Max, which results in the degradation of MYCN and subsequently either to in with of the MYCN gene, or to their development into , at which point their malignity disappears. Small chemical molecules that knock out MYCN are therefore a possible therapy option for children with neuroblastoma as well as for other MYC-driven tumours."

The molecule used by the researchers is no drug candidate; instead the finding is to be seen as a model that can inspire future cancer therapies. However, the researchers did find that the survival rate increased when they applied test treatments on mice with neuroblastoma. The study also led to a new discovery on what happens inside the cancer cell, where the treatment caused an accumulation of fat droplets, suggesting that the MYC proteins affect tumour cell metabolism and the normal breakdown of fatty acids.

"This is an original finding," says Professor Arsenian Henriksson. "It has not previously been observed that the inhibition of MYC affects tumour cells in this way. This does not only open new avenues for novel therapies for certain forms of cancer, but may also have implications for metabolic diseases, such as diabetes."


Explore further

Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs

More information: 'MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells', Hanna Zirath, Anna Frenzel, Ganna Oliynyk, Lova Segerström, Ulrica K. Westermark, Karin Larsson, Matilda Munksgaard Person, Kjell Hultenby, Janne Lehtiö, Christer Einvik, Sven Påhlman, Per Kogner, Per-Johan Jakobsson, and Marie Arsenian Henriksson, PNAS online 3-7 June 2013. www.pnas.org/cgi/doi/10.1073/pnas.1222404110
Citation: New strategy for defeating neuroblastoma found (2013, June 3) retrieved 20 September 2019 from https://medicalxpress.com/news/2013-06-strategy-defeating-neuroblastoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more